Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

"It seems enormously valuable to me." Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing.

Alzheimer's research & therapy - 6 May 2025

Graafland Charlotte H, Seelaar Harro, Panman Jessica L, Jiskoot Lize C, Kleefstra Tjitske, Poos Jackie M, Richard Edo, Schermer Maartje H N, van Swieten John C, Donker Kaat Laura, Bunnik Eline M

Abstract excerpt

BACKGROUND: Onset-predictive biomarker tests (OPBT) in genetic frontotemporal dementia (FTD) may be used to recruit mutation carriers into preventive clinical trials before symptoms manifest. This would require disclosure of OPBT results to potential participants. This study investigates the perspectives of Dutch presymptomatic mutation carriers and individuals at 50% risk of genetic FTD on disclosure of OPBT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Frontotemporal Dementia

Share to Genetic Counseling

Share to Genetic Testing

Share to Heterozygote

Share to Longitudinal Studies

Share to Netherlands

Source

Open in PubMed Open full text

Identifiers

PMID: 40329303
DOI: 10.1186/s13195-025-01749-z
PMCID: PMC12054206

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

"It seems enormously valuable to me." Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing.PMID 40329303Read ↗

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research contextSemantic proximity Read ↗

Reasons for and against presymptomatic genetic testing in frontotemporal dementia: a qualitative study.Semantic proximity Read ↗

Public perceptions of presymptomatic testing for Alzheimer disease.Semantic proximity Read ↗

How the prospect of a clinical trial impacts decision-making for predictive genetic testing in amyotrophic lateral sclerosisSemantic proximity Read ↗

How the prospect of a clinical trial impacts decision-making for predictive genetic testing in ALS.Semantic proximity Read ↗

The experience of "at-risk" status for familial frontotemporal dementia (fFTD) and its impact on reproductive decision-making: A qualitative study.Semantic proximity Read ↗

To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk.Semantic proximity Read ↗

"You're one of us now": young people describe their experiences of predictive genetic testing for Huntington disease (HD) and familial adenomatous polyposis (FAP).Semantic proximity Read ↗

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE)Semantic proximity Read ↗

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease ContinuumSemantic proximity Read ↗

Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal ResultsSemantic proximity Read ↗

Young people's moral attitudes and motivations towards direct-to-consumer genetic testing for inherited risk of Alzheimer disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.